Doxofylline is a new antibronchospastic
drug, recently introduced in
therapy, with pharmacological properties like
theophylline, a potent
adenosine receptor antagonist. The authors have investigated the occurrence, after
doxofylline administration, of the typical side-effects displayed by methylxanthines in general. The EC50 values of
doxofylline in inhibiting the
adenosine-induced relaxation of tracheal smooth muscle and the negative inotropic effect induced by
adenosine on isolated guinea-pig atria were about 15 and 10 times greater respectively than those of
aminophylline. Again,
doxofylline increased diuresis only slightly (+15.8) with 20 mg/kg os, and did not increase
sodium excretion;
aminophylline, on the contrary, produced a dose-dependent increase in urine volume and natriuresis. In mice,
aminophylline (6-24 mg/kg given intraperitoneally) dose-dependently increased locomotor activity, while
doxofylline (6-24 mg/kg, i.p.) had no effect on behaviour. In anaesthetized guinea-pigs,
doxofylline, in continuous
intravenous infusion (0.5 ml/min)
at 10 and 30 mg/ml, demonstrated fewer toxic effects than those induced by
aminophylline: the effect on diastolic blood pressure, on threshold-dose for convulsions, on death-time and on lethal dose came later than with
aminophylline. Finally,
doxofylline did not affect gastric acid secretion, either in vitro or in vivo, unlike
theophylline. The lack of side-effects with
doxofylline indicates that this
drug can be used safely and effectively in the treatment of
obstructive lung disease.